Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02675114 · ClinicalTrials.gov registry record · NA
PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis
A NA study of Aortic Stenosis, sponsored by Edwards Lifesciences.
- Active
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT02675114 is a NA study of Aortic Stenosis that is active but no longer recruiting, run by Edwards Lifesciences. The registered enrollment target is 1,000 participants, below the 1,324-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT02675114, a NA study of Aortic Stenosis, is active but no longer recruiting, sponsored by Edwards Lifesciences.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) in patients with severe, calcific aortic stenosis who are at low operative risk for standard aortic valve replacement.
Conditions Studied
Interventions
- DEVICE SAPIEN 3 THV
- PROCEDURE SAVR
Study Locations (20)
California
- Mills/Peninsula Health Services - Burlingame
- Cedars-Sinai Medical Center - Los Angeles
- University of California, Los Angeles/Ronald Reagan Medical Center - Los Angeles
- Hoag Hospital - Newport Beach
- Stanford Hospital and Clinics - Palo Alto
- Sutter Health Sacramento - Sacramento
- Kaiser Permanente San Francisco - San Francisco
Florida
- JFK Medical Center / Atlantic Clinical Research Collaborative - Atlantis
- University of Florida, Gainesville - Gainesville
- Mount Sinai Medical Center - Miami Beach
- Florida Hospital - Orlando
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
- NorthShore University HealthSystem Research Institute - Evanston
Alabama
- University of Alabama - Birmingham
Arizona
- Banner University Medical Center - Phoenix
Colorado
- UC Health Northern Colorado/Medical Center of the Rockies - Loveland
Connecticut
- Hartford - Hartford
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2016-03 |
| Est. Completion | 2029-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02675114
The ClinicalTrials.gov registry entry for NCT02675114 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,324-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (24% lower). The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Aortic Stenosis appearing as the primary indexed condition, and to 2 interventions - of which SAPIEN 3 THV is the first listed.
NCT02675114 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT02675114 about?
NCT02675114 is a clinical study titled "PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis". To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) in patients with severe, calcific aortic stenosis who are at low operative risk for standard aortic valve replacement.
What is the current status of trial NCT02675114?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2016-03. Estimated completion is 2029-12.
What conditions does trial NCT02675114 study?
This clinical trial studies the following conditions: Aortic Stenosis.
What interventions are being tested in trial NCT02675114?
The interventions under investigation include: SAPIEN 3 THV (DEVICE), SAVR (PROCEDURE).
Who is sponsoring clinical trial NCT02675114?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02675114 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Correlation Between an Impedance Cardiography Test for Decompensation and the Development of Left Ventricular Replacement Fibrosis
RECRUITING · NA
-
Evaluating Infrasonic Hemodynography
RECRUITING · NA
-
Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure
RECRUITING · NA
-
PARTNER 3 Trial - Aortic Valve-in-Valve
RECRUITING · NA
-
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
RECRUITING · NA
-
ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.